Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
Brief Summary: To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.


Options:
A: Arm Label: Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Triple-negative Breast Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: BRCA- positive Ovarian Cancer: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: ABT-888 + Cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: ABT-888, Drug: Cyclophosphamide | Arm Label: Non-Hodgkin's: Cyclophosphamide Alone; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Intervention Type: DRUG; Name: ABT-888; Assigned to Arm(s): BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): BRCA- positive Ovarian Cancer: Cyclophosphamide Alone, BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide, Non-Hodgkin's: ABT-888 + Cyclophosphamide, Non-Hodgkin's: Cyclophosphamide Alone, Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide, Triple-negative Breast Cancer: Cyclophosphamide Alone
B: Arm Label: Arm I (platinum-based chemotherapy); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Procedure: Computed Tomography, Procedure: Echocardiography Test, Drug: Gemcitabine, Drug: Gemcitabine Hydrochloride, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Paclitaxel, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm II (olaparib); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Echocardiography Test, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Arm Label: Arm III (olaparib, cediranib maleate); Type: EXPERIMENTAL; Interventions: Procedure: Biospecimen Collection, Drug: Cediranib Maleate, Procedure: Computed Tomography, Procedure: Echocardiography Test, Other: Laboratory Biomarker Analysis, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib, Other: Pharmacological Study, Other: Quality-of-Life Assessment | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Cediranib Maleate; Assigned to Arm(s): Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Echocardiography Test; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Gemcitabine Hydrochloride; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: PROCEDURE; Name: Multigated Acquisition Scan; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (platinum-based chemotherapy) | Intervention Type: OTHER; Name: Pharmacological Study; Assigned to Arm(s): Arm II (olaparib), Arm III (olaparib, cediranib maleate) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (platinum-based chemotherapy), Arm II (olaparib), Arm III (olaparib, cediranib maleate)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
D: Arm Label: Rucaparib; Type: EXPERIMENTAL; Interventions: Drug: Rucaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rucaparib; Assigned to Arm(s): Rucaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C